2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cannata-Andía, J. B. Articles by Díaz-López, B. Search for Related Content PubMed PubMed Citation Articles by Cannata-Andía, J. B. Articles by Díaz-López, B.

Vascular Calcifications: Pathogenesis, Management, and Impact on Clinical Outcomes

Bone and Mineral Research Unit, Instituto Reina Sofía de Investigación, Hospital Universitario Central de Asturias, Universidad de Oviedo, Asturias, Spain

Address correspondence to: Prof. Jorge B. Cannata-Andía, Bone and Mineral Research Unit, Hospital Universitario Central de Asturias, Julián Clavería S/N, Oviedo 33006, Spain. Phone: +34-985-106137; Fax: +34-985-106142; E-mail: cannata{at}hca.es

The predisposition to vascular calcifications in patients with chronic kidney disease (CKD) has gained great interest in recent years as many studies have described its likely impact on morbidity and mortality. The mechanism by which the process of vascular calcification is produced is complex, and it does not consist in a simple precipitation of calcium and phosphate but is instead an active and modifiable process. Several "modifiable and nonmodifiable" factors that are able to promote vascular calcification are extremely frequent in patients with CKD. Most of the present strategies to decrease vascular calcifications are based in the control of the more prevalent modifiable risk factors. Unfortunately, the extremely important nonmodifiable risk factors, which are highly prevalent, such as older age, time on dialysis, and diabetes, are not under one’s control. Recent studies also have shown that vascular calcifications in some localizations were associated with increased osteoporotic fractures not only in dialysis patients but also in the general population, and interestingly, mortality also was associated significantly and positively with vascular calcifications and nontraumatic bone fractures. Despite that new strategies may improve the management of vascular diseases and specifically have a positive impact on the high prevalence of vascular calcifications, still the best possible control of the bone metabolic and inflammatory parameters are in the primary line. The horizon of the coming decade looks promising, but solid clinical and epidemiologic data are needed to manage better the bone- and cardiovascular-related disorders in patients with CKD.

This article has been cited by other articles:

				E. Aikawa, M. Nahrendorf, J.-L. Figueiredo, F. K. Swirski, T. Shtatland, R. H. Kohler, F. A. Jaffer, M. Aikawa, and R. Weissleder Osteogenesis Associates With Inflammation in Early-Stage Atherosclerosis Evaluated by Molecular Imaging In Vivo Circulation, December 11, 2007; 116(24): 2841 - 2850. [Abstract] [Full Text] [PDF]

				D. Muller, H. Mehling, B. Otto, R. Bergmann-Lips, F. Luft, J. Jordan, and R. Kettritz Niacin Lowers Serum Phosphate and Increases HDL Cholesterol in Dialysis Patients Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1249 - 1254. [Abstract] [Full Text] [PDF]

				J. B. Cannata-Andia Changing the current terminology in medicine--Always a challenge Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1811 - 1812. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673